Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patricia Grant

Pain Medicine Pawleys Island, SC Medical Doctor

NPI 1508841156 CMS profile 249796

313B Commerce Dr, Pawleys Island, SC 29585

Open in the dashboard

General payments

$2,647

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patricia Grant of Pawleys Island, SC is reported in the CMS Open Payments database as having received $2,647 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78 3
2024 General $235 7
2023 General $281 13
2022 General $403 12
2021 General $275 13
2020 General $46 2
2019 General $1,330 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Grant
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Patricia Grant were reported at $78. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Patricia Grant Pain Medicine median Middle half National median
2019 $1,330 $498 $126–$1,682 $163
2020 $46 $284 $80–$910 $114
2021 $275 $399 $112–$1,219 $132
2022 $403 $455 $137–$1,484 $149
2023 $281 $484 $128–$1,495 $160
2024 $235 $498 $131–$1,540 $164
2025 $78 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,031 33 payments
  2. AbbVie, Inc. $135 6 payments
  3. Fidia Pharma USA Inc. $108 7 payments
  4. Collegium Pharmaceutical, Inc. $52 3 payments
  5. Vertex Pharmaceuticals Incorporated $52 2 payments
  6. Vertos Medical, Inc. $42 2 payments
  7. Nevro Corp. $40 2 payments
  8. Bioventus LLC $28 2 payments
  9. SI-BONE, Inc. $25 1 payment
  10. Medtronic USA, Inc. $21 1 payment
  11. Other $113 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,789 61 payments
  2. Travel and Lodging $858 5 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $1,258 11 payments
  2. PROCLAIM $413 13 payments
  3. Proclaim IPG $180 7 payments
  4. OCTRODE $172 1 payment
  5. HYMOVIS $92 6 payments
  6. TRILURON $81 5 payments
  7. BOTOX Neuroscience $81 3 payments
  8. BELBUCA $52 3 payments
  9. BOTOX Hyperhydrosis $46 3 payments
  10. mild Device Kit $42 2 payments
  11. Other $237 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,462

Median for Interventional Pain Management: 1,220

Drug cost

$49,591

Median for Interventional Pain Management: $39,344

Branded share of claims

29.3%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 33 $10,078
Oxycontin Oxycodone Hcl Brand 12 $7,205
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 184 $6,283
Gabapentin Generic 151 $3,964
Butrans Buprenorphine Brand 11 $3,337
Oxycodone Hcl Generic 170 $3,280
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 128 $3,003
Pregabalin Generic 120 $2,957
Fentanyl Generic 21 $2,425
Morphine Sulfate Er Morphine Sulfate Brand 47 $2,109

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$196,299

Of which drugs: $17,466

Medicare patients

349

Average age 76

Services billed

10,335

218 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 30%
Diabetes 26%
Depression 26%
Atrial fibrillation 23%
Osteoporosis 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 192 2,102 $1,605
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 130 2,427 $217
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 163 645 $67
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 12 36 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record